With a market cap of\u00a0$138.8 billion, Boston Scientific Corporation (BSX)\u00a0<\/strong>is a global medical device company that develops, manufactures, and markets innovative technologies across interventional medical specialties, operating through its MedSurg and Cardiovascular segments. It provides advanced solutions for gastrointestinal, urological, neurological, cardiovascular, and cancer-related conditions worldwide.<\/p>\n Shares of the Marlborough, Massachusetts-based company have underperformed the broader market over the past 52 weeks.\u00a0BSX stock has decreased 8.3%\u00a0over this time frame, while the broader S&P 500 Index ($SPX) has\u00a0gained 15%. Moreover, shares of the company have declined 1.6% on a YTD basis, compared to SPX’s 1.9% return.<\/p>\n Looking closer, shares of the medical device manufacturer have also lagged behind the State Street Health Care Select Sector SPDR ETF’s (XLV)\u00a05.3% rise over the past 52 weeks.<\/p>\n Shares of Boston Scientific rose nearly 4% on Oct. 22, 2025, after the company reported\u00a0better-than-expected Q3 2025 adjusted EPS of $0.75 and revenue of $5.07 billion. The company also raised its 2025 adjusted EPS forecast to $3.02 – $3.04 and guided Q4 adjusted EPS of $0.77 – $0.79, above the consensus. Investor optimism was further fueled by\u00a0strong demand for its heart devices, including a 23.1% jump in electrophysiology sales driven by the Watchman and Farapulse systems, along with improving operating margins despite tariff headwinds.<\/p>\n For the fiscal year that ended in December 2025, analysts expect BSX\u2019s\u00a0adjusted EPS to grow 21.1% year-over-year to $3.04. The company\u2019s earnings surprise history is promising. It beat the consensus estimates in the last four quarters.<\/p>\n Among the 31 analysts covering the stock, the\u00a0consensus rating is a \u201cStrong Buy.\u201d That\u2019s based on 26 \u201cStrong Buy\u201d ratings, three \u201cModerate Buys,\u201d and two \u201cHolds.\u201d<\/p>\n On Jan. 10, Bernstein analyst Lee Hambright maintained a \u201cBuy\u201d rating on Boston Scientific and set a\u00a0price target of $130.<\/p>\n The mean price target of $125.53 represents a 33.8% premium to BSX\u2019s current price levels. The Street-high price target of $140 suggests a 49.3% potential upside.<\/p>\n On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally\u00a0published on Barchart.com <\/i><\/p>\n<\/p><\/div>\n<\/div>\n<\/div>
<\/div>\n<\/div>